查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1624473

全球兰伯特伊顿肌无力症候群治疗市场规模（按类型、治疗类型、药物、最终用户、地区、范围和预测）

Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size By Type, By Treatment Type, By Drugs, By End-User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

兰伯特-伊顿肌无力症候群治疗的市场规模与预测

兰伯特伊顿肌无力症候群治疗市场规模在过去几年中成长速度较快，成长率显着，预计在预测期内，即 2024-2031 年，市场将大幅成长。

监管机构的特殊指定数量不断增加是兰伯特-伊顿肌无力症候群治疗市场收入上升的关键方面，而对新疗法的高需求将推动市场成长。全球兰伯特伊顿肌无力症候群治疗市场报告对市场进行了全面评估。它对关键细分市场、趋势、推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

定义全球兰伯特伊顿肌无力症候群治疗市场

兰伯特-伊顿肌无力症候群可能是一种影响神经肌肉接头的罕见自体免疫疾病。其特征是四肢无力、容易疲劳，自主神经功能失调，导致肌肉运动困难。它通常与小细胞肺癌（SCLC）有关。它可以发生在任何年龄。

兰伯特-伊顿肌无力症候群 (LEMS) 是一种特殊的自体免疫综合征，涉及神经肌肉接头处的不当沟通，以肌肉无力为主要临床症状。LEMS 的肌肉无力是由于针对电压门控钙通道的自身抗体减少了神经末梢的乙酰胆碱释放。对难以捉摸的临床特征和实验室异常的必要瞭解可以对 LEMS 进行初步识别。由于 LEMS 与小细胞肺癌 (SCLC) 密切相关，因此早期发现 LEMS 非常重要。儘管 LEMS 可以在 SCLC 病程的任何时间发生，但它们是早期发现该疾病的标誌，因此可能增加治疗此类恶性肿瘤的机会。患有 LEMS 的患者应该接受神经科医生和（适当情况下）肿瘤内科医生的诊治。一旦诊断，对恶性肿瘤的适当治疗是首要考虑。LEMS 的治疗包括免疫抑制剂，但这些治疗的成功取决于其毒性和使用时的麻烦。

兰伯特-伊顿肌无力症候群治疗的全球市场概况

全球兰伯特伊顿肌无力症候群治疗市场主要受到用于治疗各种神经系统疾病的新型治疗剂的需求不断增长以及製药公司集中研发活动的推动。

治疗 LEMS 的方法多种多样，包括减少抗体数量以改善肌肉功能、增加肌肉接收的乙酰胆碱量、增加身体释放的乙酰胆碱总量以及其他机制，但所有方法都涉及尚未在任何地理区域获得批准。减少抗体数量的治疗方法包括皮质类固醇、环孢菌素、硫唑嘌呤和单株抗体。降低肌肉接收乙酰胆碱的能力的治疗方法包括胆碱酯酶抑制剂。涉及增加身体乙酰胆碱生成的治疗方法包括使用氨基吡啶类药物。有药物可以治疗这种疾病，但并非所有地区都批准了这些药物。此类别包括仅在欧洲国家获得批准的氨苯吡啶。

然而，兰伯特-伊顿肌无力症候群 (LMS) 的低盛行率和有限的针对疾病的治疗选择限制了市场的成长。此外，化疗和标靶治疗的高成本也阻碍了市场的成长。此外，训练有素的人力短缺和严格的安全法规也阻碍了市场的成长。

目录

第 1 章全球兰伯特伊顿肌无力症候群治疗市场简介

  • 市场概况
  • 调查范围
  • 先决条件

第 2 章执行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

  • 数据挖掘
  • 验证
  • 一次资料
  • 数据源列表

第4章 全球兰伯特伊顿肌无力症候群治疗市场展望

  • 概述
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 波特的五力模型
  • 价值链分析

第5章全球 Lambert Eaton 肌无力症候群治疗市场按类型

  • 概述
  • 副肿瘤
  • 特发性

第6章全球 Lambert-Eaton 肌无力症候群治疗市场（依治疗类型）

  • 概述
  • 免疫疗法
  • 药物治疗
  • 血浆置换

第7章全球 Lambert-Eaton 肌无力症候群治疗市场（按药物）

  • 概述
  • 胆碱酯酶抑制剂
  • 钾通道阻断剂
  • 静脉注射免疫球蛋白
  • 其他

第8章全球 Lambert Eaton 肌无力症候群治疗市场（依最终使用者）

  • 概述
  • 医院
  • 专科诊所
  • 家庭医疗

第9章全球 Lambert-Eaton 肌无力症候群治疗市场（按地区）

  • 概述
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 世界其他地区
    • 拉丁美洲
    • 中东

第 10 章全球 Lambert Eaton 肌无力症候群治疗市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第11章 公司简介

  • Jacobus Pharmaceutical Company, Inc.
  • Zydus Cadila
  • BioMarin
  • Catalyst Pharma
  • Novartis AG
  • Shenox Pharmaceuticals, LLC.
  • Amneal Pharmaceutical LLC
  • Alvogen
  • Apnar Pharma
  • Novitium Pharma

第 12 章 附录

  • 相关研究
简介目录
Product Code: 24525

Lambert-Eaton Myasthenic Syndrome Treatment Market Size And Forecast

Lambert-Eaton Myasthenic Syndrome Treatment Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2024 to 2031.

The increase in special designation from the regulatory authorities is the crucial aspect of the rise in the market revenue of Lambert-Eaton Myasthenic Syndrome Treatment as well as the high demand for novel therapy will foster market growth. The Global Lambert-Eaton Myasthenic Syndrome Treatment Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Lambert-Eaton Myasthenic Syndrome Treatment Market Definition

Lambert-Eaton myoneural junction Lambert-Eaton syndrome may be a rare autoimmune disease that affects the neuromuscular junction. It is characterized by fatigable limb muscle weakness and autonomic dysfunction making it difficult for the movement of muscles. It is frequently associated with small-cell lung cancer (SCLC). It can occur at any age.

Lambert-Eaton Myasthenic Syndrome (LEMS) exceptional autoimmune syndrome involving improper transmission at the neuromuscular junction with the key clinical symptom of muscle weakness. Weakness in muscles in LEMS is caused due to autoantibodies to voltage-gated calcium channels resulting in the reduction of acetylcholine released from terminals of the nerve. The necessary knowledge of elusive clinical features and laboratory oddities makes the first identification of LEMS possible. Early detection of LEMS is principally significant due to its strong correlation with small cell lung cancer (SCLC). Even though LEMS can arise at any point within the path of SCLC, it is a marker for early detection of the disease, and thus permits the higher opportunity for treatment of such malignancy. Patients with LEMS should be examined then treated by both a neurologist and if appropriate, an oncologist. In the case of the diagnosis, the principal concern must be the appropriate treatment of malignancy. Treatment of LEMS includes immunosuppressant agents, but the success of the treatment depends on toxicity and trouble involved in administering the therapy.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Lambert-Eaton Myasthenic Syndrome Treatment Market Overview

The global Lambert-Eaton myasthenic syndrome treatment market is primarily driven by a rise in demand for novel therapies for the treatment of various neurological diseases and an extensive focus on research & development activities by pharmaceutical companies.

Treatment of LEMS involves various approaches that include reducing the number of antibodies to improve the muscle function, increasing the acetylcholine quantity received by the muscles, increasing the overall acetylcholine released in the body, and other mechanisms which are not approved in all the regions. The therapy involving a reduction in the number of antibodies comprises corticosteroids, cyclosporine, azathioprine, monoclonal antibodies, and many more. The therapy involving the amount of acetylcholine reception by the muscles comprises of Cholinesterase inhibitors. The therapy involving the increased amount of acetylcholine production within the body comprises of aminopyridines. There is a drug that treats the disorder but those are not approved in all the regions. This category includes amifampridine which is approved only in European countries.

However, the limited availability of disease-specific treatment options due to the low prevalence of Lambert-Eaton Myasthenic syndrome is restraining market growth. Additionally, the high cost of chemotherapy and targeted therapy is hindering the market growth. Moreover, a lack of trained personnel and stringent safety regulations is hampering the market growth.

Global Lambert-Eaton Myasthenic Syndrome Treatment Market: Segmentation Analysis

The Global Lambert-Eaton Myasthenic Syndrome Treatment Market is segmented based on Type, Treatment Type, Drugs, End User, and Geography.

Lambert-Eaton Myasthenic Syndrome Treatment Market,By Type

  • Paraneoplastic
  • Idiopathic

Based on Type, the market is bifurcated into Paraneoplastic and Idiopathic. The idiopathic segment is anticipated to dominate the global Lambert-Eaton myasthenic syndrome treatment market during the forecast period, owing to a rise in the prevalence of lung cancer and an increase in demand for brand spanking new treatment of rare diseases.

Lambert-Eaton Myasthenic Syndrome Treatment Market, By Treatment Type

  • Immune Therapy
  • Medication
  • Plasmapheresis
  • Others

Based on Treatment Type, the market is bifurcated into Immune Therapy, Medication, Plasmapheresis, and Others. The medication segment is anticipated to dominate the global Lambert-Eaton myasthenic syndrome treatment market during the forecast period.

Lambert-Eaton Myasthenic Syndrome Treatment Market, By Drugs

  • Cholinesterase Inhibitor
  • Potassium Channel Blockers
  • Intravenous Immunoglobulins
  • Others

Based on Drugs, the market is bifurcated into Cholinesterase Inhibitor, Potassium Channel Blockers, Intravenous Immunoglobulins, and Others. The cholinesterase Inhibitor segment is likely to account for a major share of the global Lambert-Eaton myasthenic syndrome treatment market.

Lambert-Eaton Myasthenic Syndrome Treatment Market, By End User

  • Hospitals
  • Specialty Clinics
  • Homecare

Based on End User, the market is bifurcated into Hospitals, Specialty Clinics, and Homecare. The hospital pharmacies segment is likely to account for a major share of the global Lambert-Eaton myasthenic syndrome treatment market, owing to an increase in awareness about rare diseases, rising availability of medicine at hospital pharmacies, and therefore the presence of skilled healthcare professionals handling autoimmune diseases.

Lambert-Eaton Myasthenic Syndrome Treatment Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of regional analysis, the Global Lambert-Eaton Myasthenic Syndrome Treatment Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The market in North America is anticipated to be driven by recent regulatory approvals from the Food and Drug Administration (FDA) and the presence of prominent pharmaceutical companies manufacturing drugs for rare disease treatment in the U.S.

Key Players

  • The "Global Lambert-Eaton Myasthenic Syndrome Treatment Market" study report will provide a valuable insight with an emphasis on the global market. The major players in the market are
  • Jacobus Pharmaceutical Company, Inc
  • Zydus Cadila
  • BioMarin
  • Catalyst Pharma
  • Novartis AG
  • Shenox Pharmaceuticals,LLC
  • Amneal Pharmaceuticals LLC
  • Alvogen
  • Apnar pharma
  • Novitium Pharma
  • The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Paraneoplastic
  • 5.3 Idiopathic

6 GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET, BY TREATMENT TYPE

  • 6.1 Overview
  • 6.2 Immune Therapy
  • 6.3 Medication
  • 6.4 Plasmapheresis

7 GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET, BY DRUGS

  • 7.1 Overview
  • 7.2 Cholinesterase Inhibitor
  • 7.3 Potassium Channel Blockers
  • 7.4 Intravenous Immunoglobulins
  • 7.5 Others

8 GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET, BY END USER

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Homecare

9 GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Rest of the World
    • 9.5.1 Latin America
    • 9.5.2 Middle East

10 GLOBAL LAMBERT-EATON MYASTHENIC SYNDROME TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Development Strategies

11 COMPANY PROFILES

  • 11.1 Jacobus Pharmaceutical Company, Inc.
    • 11.1.1 Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Outlook
    • 11.1.4 Key Developments
  • 11.2 Zydus Cadila
    • 11.2.1 Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Outlook
    • 11.2.4 Key Developments
  • 11.3 BioMarin
    • 11.3.1 Overview
    • 11.3.2 Financial Performance
    • 11.3.3 Product Outlook
    • 11.3.4 Key Developments
  • 11.4 Catalyst Pharma
    • 11.4.1 Overview
    • 11.4.2 Financial Performance
    • 11.4.3 Product Outlook
    • 11.4.4 Key Developments
  • 11.5 Novartis AG
    • 11.5.1 Overview
    • 11.5.2 Financial Performance
    • 11.5.3 Product Outlook
    • 11.5.4 Key Developments
  • 11.6 Shenox Pharmaceuticals, LLC.
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Developments
  • 11.7 Amneal Pharmaceutical LLC
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Alvogen
    • 11.8.1 Overview
    • 11.8.2 Financial Performance
    • 11.8.3 Product Outlook
    • 11.8.4 Key Developments
  • 11.9 Apnar Pharma
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Developments
  • 11.10 Novitium Pharma
    • 11.10.1 Overview
    • 11.10.2 Financial Performance
    • 11.10.3 Product Outlook
    • 11.10.4 Key Developments

12 Appendix

  • 12.1 Related Research